Payment overview · 2025
General Payments
$620.42
33 reported records · 15 companies
Healthcare provider profile · identity verified
Jay David Stevens, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FRANKLIN, PA · NPI 1760461834
Verified facts
What the public records show
CMS Open Payments records show Jay David Stevens, MD received $620.42 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Otezla, Ozempic, Paxlovid, Rexulti, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 709 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $100.90 | 16.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $79.83 | 12.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $79.01 | 12.7% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $72.55 | 11.7% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $61.49 | 9.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.13 | 9.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.29 | 5.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.18 | 3.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.37 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.89 | 2.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.20 | 2.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.88 | 2.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.79 | 2.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.52 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.39 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $620.42 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.33 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $79.83 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $72.55 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $61.49 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.24 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $57.89 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $57.13 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.49 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 319 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 131 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 303 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
319 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
319 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
131 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
303 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
709 | 89 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1067 | 271 |
| Levothyroxine Sodium | Levothyroxine Sodium | 946 | 182 |
| Lisinopril | Lisinopril | 778 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 743 | 187 |
| Eliquis | Apixaban | 709 | 89 |
| Losartan Potassium | Losartan Potassium | 617 | 141 |
| Omeprazole | Omeprazole | 562 | 151 |
| Pantoprazole Sodium | Pantoprazole Sodium | 534 | 135 |
| Gabapentin | Gabapentin | 532 | 103 |
| Furosemide | Furosemide | 456 | 112 |
| Metoprolol Tartrate | Metoprolol Tartrate | 430 | 104 |
| Metformin Hcl | Metformin Hcl | 389 | 101 |
| Citalopram Hbr | Citalopram Hydrobromide | 347 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 337 | 73 |
| Simvastatin | Simvastatin | 333 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 321 | 67 |
| Jardiance | Empagliflozin | 319 | 61 |
| Potassium Chloride | Potassium Chloride | 314 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 306 | 94 |
| Ozempic | Semaglutide | 303 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 272 | 55 |
| Tramadol Hcl | Tramadol Hcl | 271 | 67 |
| Spironolactone | Spironolactone | 248 | 64 |
| Sertraline Hcl | Sertraline Hcl | 246 | 40 |
| Famotidine | Famotidine | 228 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 226 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 224 | 59 |
| Trazodone Hcl | Trazodone Hcl | 203 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 189 | 57 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 181 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 48 |
| Prednisone | Prednisone | 179 | 88 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 177 | 41 |
| Carvedilol | Carvedilol | 169 | 38 |
| Clonazepam | Clonazepam | 169 | 31 |
| Labetalol Hcl | Labetalol Hcl | 165 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 54 |
| Ropinirole Hcl | Ropinirole Hcl | 158 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 157 | 29 |
| Lorazepam | Lorazepam | 155 | 42 |
| Metformin Hcl Er | Metformin Hcl | 149 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 143 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 143 | 39 |
| Mounjaro | Tirzepatide | 131 | 25 |
| Xarelto | Rivaroxaban | 122 | 21 |
| Ezetimibe | Ezetimibe | 119 | 28 |
| Montelukast Sodium | Montelukast Sodium | 115 | 27 |
| Alendronate Sodium | Alendronate Sodium | 114 | 33 |
| Meloxicam | Meloxicam | 114 | 34 |
| Bumetanide | Bumetanide | 110 | 24 |
| Mirtazapine | Mirtazapine | 107 | 17 |
| Donepezil Hcl | Donepezil Hcl | 106 | 18 |
| Buspirone Hcl | Buspirone Hcl | 102 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 58 |
| Valsartan | Valsartan | 93 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 92 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 32 |
| Risperidone | Risperidone | 85 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 15 |
| Memantine Hcl | Memantine Hcl | 78 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 77 | 16 |
| Bupropion Xl | Bupropion Hcl | 77 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 77 | 11 |
| Nystatin | Nystatin | 77 | 35 |
| Topiramate | Topiramate | 77 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 73 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 71 | 17 |
| Azithromycin | Azithromycin | 71 | 56 |
| Atenolol | Atenolol | 70 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 69 | 16 |
| Allopurinol | Allopurinol | 66 | 19 |
| Levetiracetam | Levetiracetam | 66 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 64 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 15 |
| Finasteride | Finasteride | 63 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 11 |
| Alprazolam | Alprazolam | 60 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 15 |
| Propranolol Hcl | Propranolol Hcl | 59 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 41 |
| Cephalexin | Cephalexin | 55 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 39 |
| Synthroid | Levothyroxine Sodium | 55 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Dutasteride | Dutasteride | 50 | suppressed |
| Myrbetriq | Mirabegron | 50 | 12 |
| Amoxicillin | Amoxicillin | 49 | 39 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 49 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 16 |
| Baclofen | Baclofen | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 45 | suppressed |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Folic Acid | Folic Acid | 38 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 17 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Budesonide | Budesonide | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 17 |
| Olanzapine | Olanzapine | 34 | suppressed |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 13 |
| Warfarin Sodium | Warfarin Sodium | 28 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 19 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Colchicine | Colchicine | 26 | 12 |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Loperamide | Loperamide Hcl | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 17 |
| Praluent Pen | Alirocumab | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 15 |
| Nitroglycerin | Nitroglycerin | 23 | 14 |
| Levofloxacin | Levofloxacin | 22 | 18 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Nadolol | Nadolol | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Otezla | Apremilast | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Clozapine | Clozapine | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Jublia | Efinaconazole | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $620.42 · 33 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PROLIA, REPATHA, REXULTI, Rybelsus, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error